

# MK-0752

Catalog No: tcsc0253



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

471905-41-6

**Formula:**

$C_{21}H_{21}ClF_2O_4S$

**Pathway:**

Stem Cell/Wnt;Neuronal Signaling

**Target:**

$\gamma$ -secretase; $\gamma$ -secretase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

442.9

## Product Description


MK-0752 is a moderately potent  $\gamma$ -secretase inhibitor, which reduces A $\beta$ 40 production with IC50 of 5 nM.

IC50 value: 5 nM (reduces A $\beta$ 40 production) [1]

Target:  $\gamma$ -secretase

in vitro: MK-0752 is identified as a moderately potent  $\gamma$ -secretase inhibitor, which reduces A $\beta$ 40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y cells [1]. In vitro, MK-0752 blocks Notch-intracellular domain (ICD) cleavage and its subsequent nuclear translocation [2].

in vivo: MK-0752 (240 mg/kg) reduces the generation of newly produced A $\beta$  with 90% decrease of AUV in the brain of rhesus monkeys. In addition, MK-0752 treatment increases levels of A $\beta$  1-14, A $\beta$  1-15, and A $\beta$  1-16 , while decreases levels of A $\beta$  1-17 [1]. In guinea-pigs, oral administration of MK-0752 (10 mg/kg -30 mg/kg) results in the dose-dependent reduction of A $\beta$ 40 in plasma, brain and cerebrospinal fluid (CSF) with IC50 of 440 nM in brain [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!